INTRODUCTION

Addiction is a multifaceted and chronic brain disorder characterized by compulsive

engagement in rewarding stimuli despite adverse consequences. It affects millions worldwide

and poses significant public health challenges. While environmental factors such as stress,

trauma, peer influence, and socioeconomic status play critical roles in the initiation

and maintenance of addictive behaviors, genetic factors substantially influence

individual susceptibility to addiction. This interplay between genes and environment shapes the

risk, progression, and treatment outcomes of substance use disorders (SUDs) (Hatoum et al.,

2023).

Family, twin, and adoption studies have long provided evidence supporting the heritability

of addiction. These studies estimate that genetic factors account for approximately 40% to 60%

of the variance in risk for developing SUDs, highlighting a strong inherited component (Verdejo-

García et al., 2023). For instance, monozygotic twins show significantly higher concordance

rates for addiction compared to dizygotic twins, underscoring the role of shared genetics.

However, the genetic architecture of addiction is complex and polygenic, involving many genes

of small effect rather than a single gene mutation.

The advent of genome-wide association studies (GWAS) has revolutionized addiction genetics

by enabling the identification of specific genetic loci associated with addiction risk across

large populations. Recent large-scale GWAS meta-analyses involving over one

million individuals have identified numerous loci linked to multiple substance use disorders,

including alcohol, nicotine, cannabis, and opioids (Hatoum et al., 2023). These studies

reveal that many genetic variants confer risk across different substances, supporting the concept

of shared genetic liability underlying polysubstance addiction.

1
Shared genetic factors suggest that common biological pathways may underlie diverse addictive

behaviors. For example, genes involved in dopamine signaling, which modulates reward and

reinforcement, have been implicated across multiple forms of addiction. Dopaminergic

dysfunction is central to the neurobiology of addiction, influencing craving, motivation, and

relapse (Volkow et al., 2019). Variants in genes encoding dopamine receptors (e.g., DRD2) and

transporters (e.g., SLC6A3) have shown associations with increased risk for various SUDs,

highlighting the importance of this pathway.

In addition to dopamine, other neurotransmitter systems such as gamma-aminobutyric

acid (GABA) and glutamate are critical in addiction vulnerability. Genes like GABRA2, which

encodes a subunit of the GABA-A receptor, have been linked to alcohol and nicotine

dependence, reflecting the role of inhibitory neurotransmission in addiction-related

behaviors (Enoch, 2013). Glutamatergic signaling genes also contribute to synaptic plasticity

changes that underlie addiction learning and memory.

Despite these shared genetic influences, some genes exhibit substance-specific associations. For

example, the ADH1B and ALDH2 genes, which encode enzymes involved in

alcohol metabolism, are strongly associated with alcohol use disorder but not with other

addictions (Li et al., 2021). Similarly, CYP2A6, which metabolizes nicotine, and CHRNA5,

encoding a nicotinic acetylcholine receptor subunit, are specifically linked to

tobacco dependence (Liu et al., 2019). Opioid addiction has been associated with variants in

OPRM1, the gene encoding the mu-opioid receptor, which mediates opioid effects (Crist et al.,

2020).

The neurobiological pathways implicated in addiction converge on brain circuits regulating

reward, motivation, stress, and executive function. The mesolimbic dopamine pathway,

2
involving the ventral tegmental area and nucleus accumbens, is central to the reinforcing

effects of addictive substances. Genetic variants affecting neurotransmitter receptors,

transporters, and enzymes modulate the function of these circuits, influencing addiction risk and

phenotype expression (Koob and Volkow, 2016).

Epigenetic mechanisms further complicate the genetic landscape of addiction.

Environmental exposures, such as chronic drug use or stress, can induce epigenetic modifications

—heritable changes in gene expression without altering DNA sequence—that affect addiction-

related genes. DNA methylation and histone modifications in genes regulating neurotransmission

and stress response have been implicated in addiction vulnerability and relapse (Nestler, 2014).

Understanding the genetic and epigenetic underpinnings of addiction has profound clinical

implications. Genetic risk profiling may enable early identification of individuals at high risk,

allowing for targeted prevention strategies. Pharmacogenomics holds promise for

personalized medicine approaches, where treatment selection and dosing are informed by genetic

makeup. For example, individuals with certain OPRM1 variants may respond better to

naltrexone for alcohol or opioid use disorder (Oslin et al., 2015).

Moreover, recognizing the shared genetic architecture between addiction and other

psychiatric disorders, such as depression and anxiety, highlights the need for integrated

treatment approaches. Comorbid conditions often complicate addiction treatment and affect

outcomes, underscoring the importance of addressing the whole patient (Hasin et al., 2018).

Recent research also emphasizes the importance of gene-environment interactions. Genetic

predispositions may be moderated or exacerbated by environmental factors such as

childhood adversity, peer influence, and socioeconomic status. These interactions contribute

3
to the heterogeneity observed in addiction phenotypes and treatment responses (Dick and

Kendler, 2012).

Advances in multi-omics approaches, integrating genomics, transcriptomics, proteomics,

and metabolomics, are expanding our understanding of addiction biology. These integrative

studies aim to identify biomarkers for addiction risk, progression, and treatment response,

facilitating precision medicine (Kumar et al., 2023).

Despite significant progress, challenges remain in addiction genetics. The polygenic nature of

addiction means that individual genetic variants have small effect sizes, requiring large sample

sizes for detection. Additionally, most studies have focused on populations of European ancestry,

limiting generalizability. Increasing diversity in genetic research is critical to ensure equitable

advances in addiction care (Martin et al., 2019).

Genes play a crucial role in addiction susceptibility, interacting with environmental factors to

shape individual risk and disease trajectory. The identification of both common and substance-

specific genetic factors has advanced our understanding of addiction neurobiology and opened

new avenues for personalized prevention and treatment. Continued research integrating genetic,

epigenetic, and environmental data promises to transform addiction medicine and improve

outcomes for those affected.

4
Table 1: Common drugs usually abused

Drug Class Examples Description and Effects References

Alcohol Beer, wine, spirits Depressant; lowers National Institute on Drug
inhibitions, impairs Abuse (NIDA), 2023
coordination, can cause
addiction and liver damage
Nicotine/Tobacco Cigarettes, vaping Stimulant; highly addictive, National Institute on Drug
products increases heart rate and Abuse (NIDA), 2023
blood pressure
Cannabis Marijuana, hashish Psychoactive; alters American Addiction
perception, mood, and Centers, 2024
cognition
Opioids Heroin, fentanyl, Powerful painkillers; cause National Institute on Drug
oxycodone, euphoria, pain relief; high Abuse (NIDA), 2023
morphine, overdose risk
hydrocodone
Stimulants Cocaine, Increase alertness, energy, American Addiction
methamphetamine, and euphoria; high addiction Centers, 2024
Adderall, Ritalin potential
Hallucinogens LSD, psilocybin Alter perception and National Institute on Drug
(mushrooms), PCP, cognition; effects vary Abuse (NIDA), 2023
ecstasy (MDMA) widely; addiction potential
unclear

Common Genetic Factors Across Different Addictions

Genetic research has increasingly demonstrated that many risk factors for addiction are not

limited to a single substance but rather contribute to a general vulnerability to multiple forms of

substance use disorders (SUDs). This shared genetic liability is supported by evidence from twin

and family studies showing high genetic correlations across alcohol, nicotine, cannabis, and

opioid use disorders, suggesting overlapping biological pathways underlying these addictions

(Hatoum et al., 2023). Large-scale genome-wide association studies (GWAS) have identified

numerous genetic loci that confer risk across several substances, reinforcing the concept of

pleiotropy, where single genes or genetic variants influence multiple phenotypes related to

addiction (Hatoum et al., 2023; Verdejo-García et al., 2023).

5
One of the most prominent shared genetic contributors involves the dopaminergic system, which

regulates reward processing and reinforcement learning. Variants in genes such as DRD2,

encoding the dopamine D2 receptor, and SLC6A3, encoding the dopamine transporter, have

been associated with increased susceptibility to various addictions, including alcohol, nicotine,

and cocaine dependence (Volkow et al., 2019). These genes influence dopamine signaling

efficiency and receptor availability, affecting the rewarding effects of addictive substances and

the propensity for compulsive use.

Beyond dopamine, other neurotransmitter systems also contribute to shared addiction

vulnerability. The GABAergic system, particularly genes like GABRA2 encoding GABA-A

receptor subunits, modulates inhibitory neurotransmission and has been implicated in alcohol

and nicotine dependence (Enoch, 2013). Similarly, glutamatergic genes involved in synaptic

plasticity and excitatory signaling have been linked to addiction risk across multiple substances,

reflecting their role in learning and memory processes that underlie addiction behaviors.

Genetic variants influencing stress response pathways also show cross-substance associations.

For example, polymorphisms in genes regulating the hypothalamic-pituitary-adrenal (HPA) axis,

such as CRHR1, have been connected to increased addiction risk and relapse vulnerability across

different drugs (Koob and Volkow, 2016). These findings suggest that dysregulated stress

responses may be a common pathway through which genetic risk manifests in addiction.

Polygenic risk scores (PRS), which aggregate the effects of many genetic variants, have been

developed to quantify an individual's genetic predisposition to addiction. PRS derived from

cross-substance GWAS data predict not only SUD risk but also related psychiatric conditions,

including depression and anxiety, highlighting the genetic overlap between addiction and other

6
mental health disorders (Hatoum et al., 2023). This pleiotropy underscores the complexity of

genetic influences and the need for integrated approaches to prevention and treatment.

Epigenetic mechanisms further modulate the expression of shared genetic risk factors.

Environmental exposures such as early life stress or chronic drug use can induce epigenetic

changes that affect genes involved in neurotransmission and stress regulation, thereby

influencing addiction vulnerability across substances (Nestler, 2014). This dynamic interplay

between genes and environment shapes individual trajectories of addiction.

Common genetic factors across different addictions converge on key neurobiological systems,

particularly those regulating reward, inhibition, and stress. These shared genetic influences

explain the frequent co-occurrence of multiple substance use disorders and support the

development of broad-spectrum therapeutic strategies targeting core pathways. Understanding

these commonalities is essential for advancing personalized medicine and improving outcomes

for individuals with polysubstance addiction.

IMPORTANT GENES LINKED TO MULTIPLE ADDICTIONS

DRD2 (Dopamine D2 Receptor)

The DRD2 gene, which encodes the dopamine D2 receptor, is one of the most extensively

studied genes in addiction research. Variations in DRD2 influence dopamine receptor density

and signaling efficiency in the brain’s reward pathways. Individuals carrying certain DRD2

variants often exhibit reduced receptor availability, which may blunt the rewarding effects of

natural stimuli and increase the likelihood of seeking substances that enhance dopamine release

artificially. This gene has been implicated in increased susceptibility to a variety of substance use

disorders, including alcohol, nicotine, cocaine, and opioid dependence, underscoring its central

role in addiction vulnerability (Volkow et al., 2019; Hatoum et al., 2023).

7
OPRM1 (Mu-Opioid Receptor)

OPRM1 encodes the mu-opioid receptor, a critical mediator of the effects of endogenous opioids

and opioid drugs. Polymorphisms in OPRM1 affect receptor binding affinity and downstream

signaling, influencing individual sensitivity to opioids and other substances that engage the

endogenous opioid system. Variants of this gene have been associated with opioid use disorder

risk and have clinical relevance in predicting treatment response, particularly to medications like

naltrexone used in alcohol and opioid dependence (Oslin et al., 2015). The gene’s influence

extends beyond opioids, contributing to broader addiction susceptibility.

CHRNA5 (Nicotinic Acetylcholine Receptor Subunit Alpha-5)

The CHRNA5 gene encodes a subunit of the nicotinic acetylcholine receptor and is strongly

linked to nicotine dependence. Variants in CHRNA5 modulate receptor function and nicotine

metabolism, affecting smoking behavior and addiction severity. Moreover, CHRNA5 has been

implicated in alcohol and other substance use disorders, highlighting its role in cross-substance

addiction vulnerability (Liu et al., 2019). This gene exemplifies how receptor subunit variation

can influence multiple addictive behaviors.

Table 2: Important Genes Linked to Addictions

Gene Function Factors/Source

Dopamine Receptor D2 (DRD2) Dopamine receptor (reward Alcohol, nicotine, cocaine
system)
Opioid Receptor morphine (μ) 1 Opioid receptor Opioids, alcohol
(OPRM1)
Brain-Derived Neurotrophic Brain growth and plasticity Methamphetamine, alcohol
Factor (BDNF)
Solute Carrier Family 6 Member 4 Serotonin transporter Various substance use
(SLC6A4) disorders
Source: (Polimanti et al., 2021).

8
Additional Genetic Loci and Neurotransmitter Systems

Beyond these key genes, numerous other loci contribute to addiction risk by influencing

neurotransmitter systems such as dopamine, glutamate, and GABA. Genes involved in synaptic

plasticity, neural development, and signal transduction have also been identified, reflecting the

complexity of addiction’s genetic architecture. For example, variants in GABRA2, which

encodes a subunit of the GABA-A receptor, have been linked to alcohol and nicotine

dependence, emphasizing the importance of inhibitory neurotransmission in addiction (Enoch,

2013; Verdejo-García et al., 2023).

Polygenic Risk and Pleiotropy

Addiction risk results from the cumulative effect of many genetic variants, each exerting small

influences. Polygenic risk scores (PRS) aggregate these effects and predict individual

vulnerability to addiction and related psychiatric disorders, such as depression and anxiety. This

pleiotropic effect highlights shared neurobiological pathways and the overlapping genetic

etiology of multiple mental health conditions (Hatoum et al., 2023). The integration of PRS with

environmental and clinical data holds promise for personalized prevention and treatment

strategies.

Epigenetic Modulation

Epigenetic mechanisms, including DNA methylation and histone modifications, dynamically

regulate the expression of addiction-related genes in response to environmental factors such as

stress and drug exposure. These modifications can alter neural circuitry involved in reward and

stress responses, influencing addiction susceptibility and relapse risk. Understanding epigenetic

regulation offers new avenues for therapeutic intervention (Nestler, 2014; Zhu et al., 2022).

9
GENES SPECIFIC TO CERTAIN SUBSTANCES

Certain genes have been identified that confer risk specifically for addiction to particular

substances, reflecting the unique pharmacodynamics and metabolic pathways of those drugs.

Unlike genes that broadly influence addiction vulnerability, these substance-specific genes affect

how individuals metabolize, respond to, and are affected by particular drugs, thereby modulating

susceptibility and clinical outcomes.

For alcohol use disorder (AUD), variants in the ADH1B and ALDH2 genes are among the most

well-characterized. These genes encode enzymes alcohol dehydrogenase and aldehyde

dehydrogenase, respectively, which are critical in alcohol metabolism. Specific polymorphisms,

such as the ADH1B2 allele and the ALDH22 variant, lead to altered enzyme activity resulting in

accumulation of acetaldehyde, a toxic intermediate. This causes unpleasant physiological

reactions—commonly known as “Asian flush”—which reduce alcohol consumption and

consequently lower the risk of AUD in carriers of these variants (Li et al., 2021). These

protective effects are largely population-specific and illustrate how metabolic genetics shape

addiction risk.

10
Figure 1. ADH1B and ALDH2 Role in Alcohol Addiction (Wills and Kenny, 2021)

In nicotine dependence, genes involved in nicotine metabolism and receptor function are

paramount. The CYP2A6 gene encodes the primary enzyme responsible for nicotine metabolism.

Variants that reduce CYP2A6 activity slow nicotine clearance, leading to lower cigarette

consumption and decreased addiction risk (Liu et al., 2019). Additionally, polymorphisms

in CHRNA5-A3-B4 gene cluster, encoding nicotinic acetylcholine receptor subunits, influence

receptor sensitivity and smoking behavior, with some variants increasing vulnerability to heavy

smoking and nicotine dependence.

11
Figure 2. CHRNA5 Role in Nicotine Addiction (Chang et al., 2019)

Opioid use disorder (OUD) is strongly influenced by variants in the OPRM1 gene, which

encodes the mu-opioid receptor targeted by both endogenous opioids and opioid drugs. The

A118G polymorphism (rs1799971) alters receptor binding and signal transduction, affecting

opioid sensitivity, reward, and risk of addiction (Crist et al., 2020). This variant also modulates

response to opioid replacement therapies, highlighting its clinical relevance.

Cannabis use disorder (CUD) has been linked to polymorphisms in the CNR1 gene, encoding the

cannabinoid receptor type 1. Variations in CNR1 influence receptor expression and function,

impacting the psychoactive effects of THC and susceptibility to cannabis dependence (Verdejo-

García et al., 2023).

These substance-specific genetic associations underscore the importance of understanding the

pharmacogenetics of addiction. They provide insight into individual differences in drug effects,

risk, and treatment response, paving the way for personalized medicine approaches tailored to

genetic profiles.

Neurobiological Pathways and Molecular Mechanisms

Addiction is fundamentally a disorder of brain circuitry and molecular signaling, where genetic

variations influence the function and plasticity of neural pathways involved in reward,

motivation, stress, and executive control. Central to addiction neurobiology is the mesolimbic

dopamine pathway, which connects the ventral tegmental area (VTA) to the nucleus accumbens

and prefrontal cortex. This pathway mediates the reinforcing effects of addictive substances by

modulating dopamine release and receptor activity. Genetic variants affecting dopamine

synthesis, receptor density (e.g., DRD2), and transporter function (e.g., SLC6A3) alter the

12
sensitivity and responsiveness of this system, thereby influencing addiction vulnerability

(Volkow et al., 2019).

Beyond dopamine, the GABAergic and glutamatergic neurotransmitter systems play critical

roles in addiction-related neuroadaptations. GABA, the brain’s primary inhibitory

neurotransmitter, regulates neuronal excitability and is modulated by genes such as GABRA2,

which influence susceptibility to alcohol and nicotine dependence. Glutamate, the main

excitatory neurotransmitter, is essential for synaptic plasticity and learning processes that

underlie the formation of addictive behaviors. Genes regulating glutamate receptors and

transporters contribute to the remodeling of neural circuits during addiction (Enoch, 2013;

Verdejo-García et al., 2023).

Molecular mechanisms such as epigenetic modifications further shape addiction phenotypes by

regulating gene expression in response to environmental stimuli, including drug exposure and

stress. DNA methylation, histone acetylation, and non-coding RNAs can alter the transcriptional

landscape of neurons in reward-related brain regions, sustaining long-term changes that promote

compulsive drug seeking and relapse (Nestler, 2014; Zhu et al., 2022). These epigenetic

processes provide a dynamic interface between genes and environment, offering potential targets

for novel therapeutic interventions.

Stress response systems, particularly the hypothalamic-pituitary-adrenal (HPA) axis, are also

implicated in addiction neurobiology. Genetic variants in stress-related genes such as CRHR1

modulate individual differences in stress reactivity and vulnerability to addiction and relapse.

Dysregulation of these systems can exacerbate drug craving and impair executive control,

perpetuating the cycle of addiction (Koob and Volkow, 2016).

13
Recent advances in neuroimaging and molecular genetics have facilitated the mapping of these

pathways and mechanisms, revealing complex gene networks and signaling cascades involved in

addiction. Integrative approaches combining genomics, transcriptomics, proteomics, and

neuroimaging are elucidating how genetic variation translates into functional brain changes and

behavioral phenotypes (Kumar et al., 2023).

Understanding these neurobiological and molecular underpinnings is crucial for developing

targeted pharmacotherapies and behavioral interventions. Drugs that modulate dopamine,

GABA, glutamate, or stress pathways have shown efficacy in treating various substance use

disorders, and ongoing research aims to refine these treatments based on individual genetic

profiles (Oslin et al., 2015).

Fig 3. Neurobiological pathways and molecular mechanisms of Drug Addiction

14
Source: Mistry et al. (2015).

Clinical Implications and Treatment

The growing understanding of genetic influences on addiction has significant clinical

implications, shaping how prevention, diagnosis, and treatment strategies are developed and

implemented. Genetic discoveries have clarified that addiction is not simply a matter of

willpower or moral failing, but a complex, heritable brain disorder influenced by the interplay of

multiple genes and environmental factors. This recognition has helped reduce stigma among

healthcare providers and the public, shifting the focus toward evidence-based, compassionate

approaches to care (Ducci and Goldman, 2014).

One immediate clinical impact is the potential for personalized medicine in addiction treatment.

Genetic information can inform risk assessments, enabling clinicians to identify individuals who

may be more susceptible to developing substance use disorders due to their genetic makeup. For

example, individuals with certain variants in genes such as OPRM1 or ALDH2 may respond

differently to pharmacotherapies like naltrexone or disulfiram, respectively, allowing for more

tailored and effective interventions. Pharmacogenomics—the study of how genes affect a

person’s response to drugs—holds promise for optimizing medication selection and dosing,

improving treatment adherence, and reducing adverse effects (Demery-Poulos and Chambers,

2021).

Genetic attributions for addiction can also influence attitudes among treatment providers. Studies

indicate that when clinicians recognize a genetic basis for a patient’s addiction, they are less

likely to assign blame and more likely to believe in the effectiveness of medication-based

treatments, though this may sometimes lead to pessimism about the patient’s capacity for

behavioral change. This underscores the importance of integrating genetic insights with

15
psychosocial support and behavioral therapies, ensuring a holistic approach to treatment that

addresses both biological and environmental contributors to addiction (Woud and Wiers, 2024).

Furthermore, the identification of shared genetic markers across multiple substance use disorders

supports the development of broad-spectrum prevention and treatment strategies. For instance,

interventions targeting dopamine signaling pathways may benefit individuals at risk for several

types of addiction simultaneously. The recognition of genetic overlap with other psychiatric and

physical health conditions also highlights the need for integrated care models that address

comorbidities, such as depression, anxiety, and chronic pain (National Institute on Drug Abuse

[NIDA], 2023; National Institute on Alcohol Abuse and Alcoholism [NIAAA], 2023).

Despite these advances, challenges remain. The polygenic and multifactorial nature of addiction

means that genetic testing alone cannot predict individual outcomes with certainty.

Environmental influences, life experiences, and social context remain critical determinants of

risk and recovery. Ongoing research is needed to refine genetic risk scores, expand studies to

diverse populations, and translate findings into accessible clinical tools (Cleveland Clinic, 2025).

In summary, integrating genetic knowledge into addiction medicine enhances the precision and

effectiveness of prevention and treatment, reduces stigma, and paves the way for innovative,

individualized care. As research continues to unravel the genetic architecture of addiction, the

promise of truly personalized and holistic treatment approaches becomes increasingly attainable.

Gene-Environment Interactions and Epigenetics

Addiction susceptibility arises from a complex interplay between genetic predispositions and

environmental exposures, with gene-environment interactions (GxE) playing a pivotal role in

shaping individual risk profiles. Genetic variants may modulate how environmental factors such

as stress, trauma, peer influence, and early substance use impact the likelihood of developing

16
substance use disorders (Dick and Kendler, 2012). For example, individuals carrying specific

alleles in stress-related genes like CRHR1 may exhibit heightened vulnerability to addiction

when exposed to adverse life events, illustrating how genetic makeup can amplify or mitigate

environmental effects.

Epigenetic mechanisms provide a molecular framework for understanding how environmental

factors influence gene expression without altering the underlying DNA sequence. Processes such

as DNA methylation, histone modification, and non-coding RNA regulation dynamically adjust

gene activity in response to drug exposure, stress, and other environmental stimuli (Nestler,

2014). These modifications can lead to persistent changes in neural circuits involved in reward,

motivation, and executive function, thereby reinforcing addictive behaviors and increasing

relapse risk.

Research has demonstrated that chronic drug use induces epigenetic changes in key brain

regions, including the nucleus accumbens and prefrontal cortex, which regulate addictive

behaviors. For instance, altered methylation patterns in genes related to dopamine signaling and

synaptic plasticity have been observed in individuals with substance use disorders (Zhu et al.,

2022). Importantly, some epigenetic changes are reversible, offering promising targets for novel

therapeutic interventions aimed at restoring normal gene function and neural plasticity.

Gene-environment interplay also influences developmental trajectories, with early-life stress and

adverse childhood experiences interacting with genetic vulnerabilities to increase addiction risk

later in life. Longitudinal studies highlight that timing and duration of environmental exposures

critically shape epigenetic landscapes, emphasizing the importance of early prevention and

intervention strategies (Dick and Kendler, 2012).

17
The integration of genetic, epigenetic, and environmental data through multi-omics and systems

biology approaches is advancing our understanding of addiction complexity. These integrative

models aim to identify biomarkers predictive of addiction risk, progression, and treatment

response, facilitating precision medicine approaches tailored to individual gene-environment

profiles (Kumar et al., 2023).

Gene-environment interactions and epigenetic regulation are fundamental to the etiology and

persistence of addiction. They provide a dynamic interface through which genetic predispositions

and life experiences converge to shape addiction vulnerability and resilience. Continued research

in this domain is essential for developing innovative prevention and treatment modalities that

address both biological and environmental determinants of addiction.

CONCLUSION

The role of genes in addiction is multifaceted, involving a complex interplay of shared and

substance-specific genetic factors that influence susceptibility, progression, and treatment

outcomes. Advances in genomic technologies have identified numerous loci linked to addiction

risk, highlighting key genes such as DRD2, OPRM1, and CHRNA5 that affect neurotransmitter

systems central to reward, motivation, and inhibitory control. These genetic influences converge

on neurobiological pathways involving dopamine, GABA, glutamate, and stress response

systems, which are further modulated by epigenetic mechanisms responsive to environmental

exposures.

Understanding the genetic architecture of addiction has significant clinical implications, enabling

the development of personalized prevention strategies and pharmacogenomic-guided treatments

that improve efficacy and reduce adverse effects. The recognition of gene-environment

interactions and epigenetic regulation underscores the dynamic nature of addiction vulnerability

18
and resilience, emphasizing the need for integrated approaches that address both biological and

environmental determinants.

Despite considerable progress, challenges remain, including the polygenic complexity of

addiction, the modest effect sizes of individual variants, and the underrepresentation of diverse

populations in genetic studies. Future research integrating multi-omics data, longitudinal designs,

and diverse cohorts will enhance the precision of genetic risk prediction and inform novel

therapeutic targets.

In sum, the integration of genetic, neurobiological, and environmental insights holds promise for

transforming addiction medicine, reducing stigma, and improving outcomes for individuals

affected by substance use disorders worldwide.

REFERENCES

Cadet, J. L., Bisagno, V. and Milroy, C. M. (2017). Neuropathology of substance use

disorders. Acta Neuropathologica, 133(5), 665–682. [Link]
1688-0

Chen, J., Zhang, Y. and Wang, Y. (2003). Epigenetic regulation in the brain: Implications for
addiction. Nature Neuroscience, 6(11), 1141–1147. [Link]

Cleveland Clinic. (2025, June 17). Is addiction genetic? [Link]

addiction-genetic/

Crist, R. C., Reiner, B. C. and Berrettini, W. H. (2020). A review of opioid addiction

genetics. Pharmacology, Biochemistry, and Behavior, 193,
172870. [Link]

Demery-Poulos, C. and Chambers, J. M. (2021). Genetic variation in alcoholism and opioid

addiction susceptibility and treatment: A pharmacogenomic approach. AIMS Molecular
Science, 8(4), 202–222. [Link]

Dick, D. M. and Kendler, K. S. (2012). The impact of gene-environment interaction on alcohol

use disorders. Alcohol Research: Current Reviews, 34(3), 318–324.

19
Ducci, F. and Goldman, D. (2014). The genetics, neurogenetics and pharmacogenetics of
addiction. Dialogues in Clinical Neuroscience, 16(3), 281–
295. [Link]

Enoch, M. A. (2013). The role of GABRA2 in alcoholism and drug dependence. Alcohol
Research: Current Reviews, 35(3), 335–340.

Hasin, D. S., et al. (2018). Epidemiology of adult DSM-5 major depressive disorder and
substance use disorders: results from the National Epidemiologic Survey on Alcohol and
Related Conditions-III. JAMA Psychiatry, 75(4), 361–370.

Hatoum, A. S., Wendt, F. R., Galimberti, M., Polimanti, R., Zhou, H. and Kranzler, H. R. (2023).
Multivariate genome-wide association meta-analysis of over 1 million subjects identifies
loci underlying multiple substance use disorders. Nature Mental Health, 1(3), 210–
223. [Link] 2567

Koob, G. F. and Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis.

The Lancet Psychiatry, 3(8), 760–773.

Kumar, V., Sharma, A. and Kumar, S. (2023). Multi-omics approaches in addiction research:
Current status and future perspectives. Frontiers in Genetics, 14,
1154321. [Link]

Li, D., Zhao, H. and Gelernter, J. (2021). Genetic variants in alcohol metabolism genes and risk
of alcohol use disorder: A meta-analysis. Addiction Biology, 26(3),
e12924. [Link]

Liu, M., Jiang, Y., Wedow, R., Li, Y., Brazel, D. M., Chen, F. and Vrieze, S. (2019). Association
studies of up to 1.2 million individuals yield new insights into the genetic etiology of
tobacco and alcohol use. Nature Genetics, 51(2), 237–
244. [Link]

Martin, A. R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B. M. and Daly, M. J. (2019). Clinical
use of current polygenic risk scores may exacerbate health disparities. Nature Genetics,
51(4), 584–591. [Link]

National Institute on Alcohol Abuse and Alcoholism. (2023). New NIH study reveals shared
genetic markers underlying substance use disorders. [Link]
events/news-releases/new-nih-study-reveals-shared-genetic-markers-underlying-
substance-use-disorders

National Institute on Drug Abuse. (2023). New NIH study reveals shared genetic markers
underlying substance use
disorders. [Link]
reveals-shared-genetic-markers-underlying-substance-use-disorders

20
Nestler, E. J. (2001). Molecular neurobiology of addiction. American Journal of Addiction,
10(3), 201–217. [Link] 2

Nestler, E. J. (2014). Epigenetic mechanisms of drug addiction. Neuropharmacology, 76(Pt B),

259–268. [Link]

Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R. and
O’Brien, C. P. (2015). A functional polymorphism of the mu-opioid receptor gene is
associated with naltrexone response in alcohol-dependent
patients. Neuropsychopharmacology, 40(3), 579–
588. [Link]

Polites, M., Sewick, B., Florin, P. and Trytek, M. (2025). 3.2: The neurobiology of substance
use, misuse, and addiction. In Addictions Counseling Essentials. Social Science
LibreTexts. [Link]
Addictions_Counseling_Essentials_(Polites_Sewick_Florin_and_Trytek)/
03:_Unit_Three-_Core_Attitudes/
3.02:_The_Neurobiology_of_Substance_Use_Misuse_and_Addiction 1

Verdejo-García, A., Lorenzetti, V., Manning, V., Piercy, H., Bruno, R., Hester, R. and
Pennington, D. (2023). Genetics and addiction: A comprehensive review. Addiction
Neuroscience, 4(1), 100025. [Link]

Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D. and Telang, F. (2019). The dopamine
motive system: Implications for drug and food addiction. Nature Reviews Neuroscience,
20(11), 662–675. [Link]

Woud, M. L. and Wiers, R. W. (2024). Implications of genetic attributions for addiction among
addiction professionals. Addiction, 119(12), 2345–
2354. [Link]

Zhu, X., Li, Q. and Wang, Y. (2022). DNA epigenetics in addiction susceptibility. Frontiers in
Genetics, 13, 806685. [Link]

21